Lipid formulations of amphotericin

被引：13

作者：

Botero, Martha C. ^{[1
]}

Puentes-Herrera, Marcela ^{[1
]}

Cortes, Jorge A. ^{[2
]}

机构：

[1] Univ Nacl Colombia, Fac Med, Dept Med Interna, Bogota, Colombia

[2] Univ Nacl Colombia, Grp Invest Enfermedades Infecciosas, Bogota, Colombia

来源：

REVISTA CHILENA DE INFECTOLOGIA | 2014年 / 31卷 / 05期

关键词：

Amphotericin B; fungemia; drug toxicity; histoplasmosis; aspergillosis; candidemia; candidiasis; invasive; cryptococcosis; zygomycosis; leishmaniasis; MULTICENTER RANDOMIZED-TRIAL; CLINICAL-PRACTICE GUIDELINES; INFECTIOUS-DISEASES SOCIETY; HEMATOLOGIC MALIGNANCIES; DOUBLE-BLIND; VISCERAL LEISHMANIASIS; INVASIVE ASPERGILLOSIS; ANTIFUNGAL THERAPY; SALVAGE THERAPY; B AMBISOME;

D O I：

10.4067/S0716-10182014000500002

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Amphotericin B deoxycholate use has increased during the past years in parallel with the increase in the number of immunosuppressed patients suffering invasive fungal infections. This drug is associated with a high rate of side effects, especially renal toxicity. Lipid formulations (liposomal, lipid complex, colloidal suspension and the Indian liposomal formulation) have been developed, which share the same antifungal spectrum but differ in efficacy and toxicity. A review of amphotericin lipid formulations is presented, focusing on differences in efficacy and, especially renal toxicity. The main problem for use of these formulations in Latin America is their highcost.

引用

页码：518 / 527

页数：10

共 50 条

[21] Penetration of amphotericin B lipid formulations into pleural effusion
Weiler, Stefan
Bellmann-Weiler, Rosa
Joannidis, Michael
Bellmann, Rornuald
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (11) : 4211 - 4213
[22] Pulmonary extraction and accumulation of lipid formulations of amphotericin B
Matot, I
Pizov, R
CRITICAL CARE MEDICINE, 2000, 28 (07) : 2528 - 2532
[23] Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia
Johansen, Helle Krogh
Gotzsche, Peter C.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (09):
[24] Treatment of systemic neonatal candidiasis with lipid formulations of amphotericin B
Krebs, VLJ
Galvani, ALS
Feferbaum, R
Diniz, EMA
Ceccon, MEJ
Dória, U
Vaz, FAC
4TH WORLD CONGRESS OF PERINATAL MEDICINE, 1999, : 63 - 67
[25] Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia
Frothingham, R
CLINICAL INFECTIOUS DISEASES, 2002, 35 (07) : 896 - 897
[26] Nutritional impact of lipid-associated amphotericin B formulations
Sacks, GS
Cleary, JD
ANNALS OF PHARMACOTHERAPY, 1997, 31 (01) : 121 - 122
[27] LIPOSOMAL AND LIPID FORMULATIONS OF AMPHOTERICIN-B - CLINICAL PHARMACOKINETICS
JANKNEGT, R
DEMARIE, S
BAKKERWOUDENBERG, IAJM
CROMMELIN, DJA
CLINICAL PHARMACOKINETICS, 1992, 23 (04) : 279 - 291
[28] AMPHOTERICIN-B AND ITS DELIVERY BY LIPOSOMAL AND LIPID FORMULATIONS
GATES, C
PINNEY, RJ
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1993, 18 (03) : 147 - 153
[29] Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations
Groll, Andreas H.
Lyman, Caron A.
Petraitis, Vidmantas
Petraitiene, Ruta
Armstrong, Derek
Mickiene, Diana
Alfaro, Raul M.
Schaufele, Robert L.
Sein, Tin
Bacher, John
Walsh, Thomas J.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) : 3418 - 3423
[30] Lipid formulations of amphotericin B in the management of invasive fungal infections
Fohrer, Cecile
Nivoix, Yasmine
Moulin, Jean-Charles
Marcais, Ambroise
Herbrecht, Raoul
THERAPIE, 2006, 61 (03): : 235 - 242

← 1 2 3 4 5 →